ClinicalTrials.gg
CompletedNCT04565236Updated Apr 18, 2025Results posted

A Post Approval Commitment Study to Gain More Information on How Safe and Effective KOVALTRY is in Chinese Children, Adolescents /Adults With Severe Hemophilia A

A Phase 4 interventional study of Recombinant Factor VIII (Kovaltry, BAY81-8973) Treatment Group 1 and Recombinant Factor VIII (Kovaltry, BAY81-8973) Treatment Group 2 in Hemophilia A, sponsored by Bayer. Completed at 10 sites in China. Open to male participants aged 0 Years to 65 Years. Per ClinicalTrials.gov, last updated 2025-04-18.

Sponsored by Bayer · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
45
Allocation
Non-randomized
Ages
0 Years to 65 Years
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 57 studies in Hemophilia A by Bayer — 3 open to participants now, 6 under way, none of them phase 3. Hemophilia A · Bayer.

Enrollment
9th of 31
45 · median 27
Started
2020
the only one that year
Phase 4
8 of 57
none open now
Registered
50th of 57
by date

Among the 57 studies in Hemophilia A by Bayer, this one is the 9th largest by enrollment of the 31 interventional ones that give a count, is the only one that started in 2020, is one of 8 in phase 4, and was the 50th registered.

Hemophilia A

844 studies on the registry are indexed under Hemophilia A; 136 are open to participants now.

Browse Hemophilia A studies →

Open to participants now

3 of the 57 studies in Hemophilia A by Bayer are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

Who these studies take

Of the 87 Hemophilia A studies recruiting now, 51 (59%) set no upper age limit and 31 (36%) stop at 75 or younger; 55 take children under 18; 10 take healthy volunteers.

This study: 0 Years to 65 Years · male · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 57 studies in Hemophilia A by Bayer, or all of them as a file.
02

Study summary

The goal of this study is to gather more information on safety and efficacy of Kovaltry for the prevention and treatment of bleeds in Chinese children, adolescents/adults with severe hemophilia A. In addition, pharmacokinetic parameters of Kovaltry will be assessed in a subset of patients.

03

Conditions studied

  • Hemophilia A

Browse trials for

04

Who can participate

Ages eligible
0 Years to 65 Years
Sexes eligible
Male
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Part A (PTPs):

  • Chinese participants with severe hemophilia A (defined as Factor VIII (FVIII): C \< 1% with one- stage clotting assay documented at the time of screening)
  • Currently receiving on-demand or any type of prophylaxis treatment regimen with any FVIII product
  • For participants \< 12 years of age, ≥ 50 exposure days (ED); for participants ≥ 12 to 65 years of age, ≥ 150 ED with any FVIII product
  • No current evidence of inhibitor
  • No history of FVIII inhibitor formation
  • Signed

Part B (PUPs/MTPs):

  • Participants must be \<6 years of age at the time of their parent or legal representative's signature of informed consent on the participant's behalf
  • Chinese participants with severe hemophilia A (defined as Factor VIII (FVIII): C \< 1% with one- stage clotting assay documented at the time of screening)
  • PUPs must have no previous exposure to any FVIII product. MTPs must have no more than 1 ED with any purified FVIII concentrate or 3 exposures with FFP or cryoprecipitate.
  • MTPs must have no current evidence of inhibitor antibody as measured by the Nijmegen-modified Bethesda assay (\<0.6 BU/mL) in 2 consecutive samples and must have absence of clinical signs or symptoms of decreased response to FVIII administration. Testing for the 2 negative samples must be performed by the central laboratory at least 1 week but not more than 2 weeks apart. Participants may not receive FVIII product within 72 hours prior to the collection of samples for inhibitor testing.
  • PUPs and MTPs must observe a 6-month if they have received subcutaneous factor substitution therapy (emicizumab).
  • PUPs may be included if they will receive their first FVIII dose with KOVALTRY for treatment of first bleed and agree to start prophylaxis as part of their care. MTPs may be included if they agree to start prophylaxis as part of their care.

Exclusion criteria

Exclusion Criteria:

Part A (PTPs):

  • Any other bleeding disease that is different from hemophilia A (e.g. von Willebrand disease, hemophilia B)
  • count \< 100 000/mm\^3
  • Impaired renal function (serum creatinine > 2.0 mg/dL) or active liver disease (/aspartate aminotransferase [ALT/AST] > 5x )
  • (HIV) positive with an absolute CD4 lymphocyte cell count \< 250 cells/μL
  • Known to the active substance, mouse or hamster protein
  • Receiving chemotherapy, immune modulatory drugs other than anti-retroviral chemotherapy, or chronic use of oral or intravenous (IV) (> 14 days) within the last 3 months.
  • Requiring any pre-medication to tolerate FVIII infusions (e.g. antihistamines)
  • Currently participating in another drug study, or having previously participated in a clinical study involving an investigational drug within 30 days of signing or participated in completed interventional clinical studies with BAY81-8973 (Kovaltry)
  • Planned major surgery, defined as surgery with respiratory assistance and/or general anesthesia

Part B (PUPs/MTPs):

  • Any other bleeding disease that is different from hemophilia A (e.g. von Willebrand disease, hemophilia B)
  • Platelet count \< 100 000/mm\^3
  • Impaired renal function (serum creatinine >2× upper limit of normal [ULN]) or active liver disease (alanine aminotransferase [ALT] or aspartate aminotransferase [AST] >5× ULN) based on screening laboratory assessments
  • MTPs with history of FVIII inhibitor formation
  • Known hypersensitivity to the active substance, mouse or hamster protein
  • First treatment with KOVALTRY for high risk bleeding situations (e.g., surgery, intracranial bleed) or requiring intensive or prolonged treatment
  • Receiving chemotherapy, immune modulatory drugs other than anti-retroviral chemotherapy, or chronic use of oral or intravenous (IV) corticosteroids (> 14 days) within the last 3 months.
  • Requiring any pre-medication to tolerate FVIII infusions (e.g. antihistamines)
  • Currently participating in another investigational drug study, or having previously participated in a clinical study involving an investigational drug within 30 days of signing informed consent or participated in completed interventional clinical studies with BAY 81-8973 (Kovaltry)
  • Planned major surgery, defined as surgery with respiratory assistance and/or general anesthesia
  • Unable to tolerate volume of blood draws required for study participation
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
45 participants (actual)

Study arms

  • Experimental
    Part A: PTPs <12 years of age

    Previously treated severe hemophilia A patients (PTPs) \<12 years of age

    Biological: Recombinant Factor VIII (Kovaltry, BAY81-8973) Treatment Group 1

  • Experimental
    Part A: PTPs ≥12 to 65 years of age

    Previously treated severe hemophilia A patients (PTPs) ≥12 to 65 years of age

    Biological: Recombinant Factor VIII (Kovaltry, BAY81-8973) Treatment Group 2

  • Experimental
    Part B: PUPs/MTPs <6 years of age

    Previously untreated/minimally treated severe hemophilia A patients (PUPs/MTPs) \<6 years of age

    Biological: Recombinant Factor VIII (Kovaltry, BAY81-8973) Treatment Group 3

Interventions

  • BiologicalRecombinant Factor VIII (Kovaltry, BAY81-8973) Treatment Group 1

    25 to 50 IU of Kovaltry per kg body weight given via intravenous (IV) infusion twice weekly, three times weekly, or every other day according to individual requirements for 6 months. The dose decisions are at the discretion of the investigator.

  • BiologicalRecombinant Factor VIII (Kovaltry, BAY81-8973) Treatment Group 2

    12 year-old: 25 to 50 IU of Kovaltry per kg body weight given via intravenous (IV) infusion twice weekly, three times weekly, or every other day for 6 months. \>12 year-old: 20 to 40 IU of Kovaltry per kg of body weight given via intravenous (IV) infusion two or three times per week for 6 months. The dose decisions are at the discretion of the investigator.

  • BiologicalRecombinant Factor VIII (Kovaltry, BAY81-8973) Treatment Group 3

    15 to 50 IU of Kovaltry per kg body weight (minimum dose: 250 IU) given via intravenous (IV) infusions at least once a week. The dose decisions are at the discretion of the investigator.

06

What researchers measure

Primary outcomes

  1. Annualized Bleeding Rate (ABR) of All Bleeding Episodes During Prophylaxis Treatment in Part A

    Annualized number (mean +/- standard deviation) of all bleeding episodes that occurred during the prophylaxis treatment period is reported for previously treated patients (PTPs). All bleeding episodes: sum of spontaneous bleeds and trauma bleeds exclude bleeding due to surgery.

    Time frame: Up to 6 months

  2. Annualized Bleeding Rate (ABR) of All Bleeding Episodes Within 48 Hours of Previous Prophylaxis Infusion in Part B

    Annualized number (mean +/- standard deviation) of all bleeding episodes that occurred within 48 hours of previous prophylaxis infusion is reported for previously untreated/minimally treated patients (PUPs/MTPs). All bleeding episodes: sum of spontaneous bleeds and trauma bleeds exclude bleeding due to surgery.

    Time frame: Up to 48 hours post-infusion during 6 months

Secondary outcomes

  1. Annualized Bleeding Rate (ABR) of All Bleeding Episodes Within 48 Hours of Previous Prophylaxis Infusion in Part A

    Annualized number (mean +/- standard deviation) of all bleeding episodes that occurred within 48 hours of previous prophylaxis infusion is reported for previously treated patients (PTPs). All bleeding episodes: sum of spontaneous bleeds and trauma bleeds exclude bleeding due to surgery.

    Time frame: Up to 48 hours post-infusion during 6 months

  2. Annualized Bleeding Rate (ABR) of All Bleeding Episodes During Prophylaxis Treatment in Part B

    Annualized number (mean +/- standard deviation) of all bleeding episodes that occurred during the prophylaxis treatment period is reported for previously untreated/minimally treated patients (PUPs/MTPs). All bleeding episodes: sum of spontaneous bleeds and trauma bleeds exclude bleeding due to surgery.

    Time frame: Up to 51 exposure days

  3. Number of Infusions Per Bleeding Episode

    The mean value of number of infusions for the treatment of one bleed to achieve hemostasis is reported.

    Time frame: Part A: up to 6 months; Part B: up to 51 exposure days

  4. Number of Surgeries Per Physician's Assessment of Adequacy of Hemostasis in Minor Surgery

    For participants who underwent minor surgeries during the study, investigators were ask to assess the adequacy of hemostasis during the surgeries as excellent, good, moderate or poor. Number of surgeries per assessment is reported.

    Time frame: Part A: up to 6 months; Part B: up to 51 exposure days

  5. FVIII In-vivo Recovery in Part B

    Incremental recovery of Factor VIII (FVIII) was determined by collecting blood samples pre-infusion and 15-30 minutes after the end of the infusion. Mean recovery values at different time points are reported.

    Time frame: At baseline, Visit 6 (ED 20), unscheduled visit and final visit, up to 51 exposure days

  6. Factor VIII Inhibitor Development by the Nijmegen Bethesda Assay

    Number of participants who developed a positive Factor VIII (FVIII) inhibitor level (≥0.6 Bethesda unit \[BU/mL\]) during the study is reported.

    Time frame: Part A: up to 6 months; Part B: up to 51 exposure days

  7. Number of Participants With Treatment-emergent Adverse Events

    An adverse event (AE) was any untoward medical occurrence in a participant, associated with the use of study intervention, whether or not considered related to the study intervention. A serious adverse event (SAE) was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening; persistent or significant disability/incapacity; congenital anomaly/birth defect; another medical important serious event as judged by the investigator. AEs or SAEs were considered to be treatment emergent (TEAEs or TESAEs) if they started after the first KOVALTRY infusion and up to 3 days after the last dose.

    Time frame: Part A: up to 6 months; Part B: up to 51 exposure days

  8. FVIII In-vivo Recovery in Part A

    Incremental recovery of Factor VIII (FVIII) was determined by collecting blood samples pre-infusion and 15-30 minutes after the end of the infusion. Mean recovery values at different time points are reported.

    Time frame: At baseline, Month 2 and final visit, up to 6 months

  9. Maximum Observed Concentration of FVIII in Plasma (Cmax) in Part A

    For the assessment, participants were administered a dose of 50 IU/kg KOVALTRY. Participants must have no signs or symptoms of an acute bleeding episode. For participants below 12 years, the evaluation was only performed once at baseline. For adolescents/adult participants 12 years or older, the evaluation was performed twice at baseline and at final visit.

    Time frame: at baseline for PTPs < 12 Years and at baseline and final visit (month 6) for PTPs >= 12 Years

  10. Area Under the Plasma Concentration of FVIII Versus Time Curve From Zero to Infinity (AUC) in Part A

    For the assessment, participants were administered a dose of 50 IU/kg KOVALTRY. Participants must have no signs or symptoms of an acute bleeding episode. For participants below 12 years, the evaluation was only performed once at baseline. For adolescents/adult participants 12 years or older, the evaluation was performed twice at baseline and at final visit.

    Time frame: at baseline for PTPs < 12 Years and at baseline and final visit (month 6) for PTPs >= 12 Years

  11. Half-life (t1/2) of FVIII in Plasma in Part A

    For the assessment, participants were administered a dose of 50 IU/kg KOVALTRY. Participants must have no signs or symptoms of an acute bleeding episode. For participants below 12 years, the evaluation was only performed once at baseline. For adolescents/adult participants 12 years or older, the evaluation was performed twice at baseline and at final visit.

    Time frame: at baseline for PTPs < 12 Years and at baseline and final visit (month 6) for PTPs >= 12 Years

Other outcomes

  1. Number of Participants Without Bleeding Episode

    Number of participants who did not experience any bleed during the prophylaxis treatment period or within 48 hours of previous prophylaxis infusion is reported.

    Time frame: During prophylaxis treatment in Part A: up to 6 months; Part B: up to 51 exposure days

  2. Number of Bleeds Per Assessment of Response to Treatment of Bleeds

    Participants or caregivers were asked to assess the response to treatment of bleeds as excellent, good, moderate or poor. Number of bleeds per assessment is reported.

    Time frame: Part A: up to 6 months; Part B: up to 51 exposure days

07

Results

Posted Apr 18, 2025
Limitations and caveats
Results of ABR of treated/target joint bleeding episodes and FVIII usage are not reported as they are other pre-defined endpoints per protocol.

Participant flow

The Part A of study was conducted in multicenter in China between 22 SEP 2020 and 04 JAN 2022. The Part B of study was conducted in multicenter in China between 07 SEP 2021 and 15 MAR 2024.

Participant flow — Overall Study
MilestonePart A: PTPs <12 YearsPart A: PTPs ≥12 YearsPart B: PUPs <6 YearsPart B: MTPs <6 Years
Started301221
Completed301211
Not completed0010
Withdrew: Patient/guardian decision0010

Outcome measures

PrimaryAnnualized Bleeding Rate (ABR) of All Bleeding Episodes During Prophylaxis Treatment in Part A

Annualized number (mean +/- standard deviation) of all bleeding episodes that occurred during the prophylaxis treatment period is reported for previously treated patients (PTPs). All bleeding episodes: sum of spontaneous bleeds and trauma bleeds exclude bleeding due to surgery.

Time frame:
Up to 6 months
Reported as:
Mean · Bleed per year
Annualized Bleeding Rate (ABR) of All Bleeding Episodes During Prophylaxis Treatment in Part A
Bleed per yearPart A: PTPs ≥12 YearsPart A: PTPs <12 Years
Annualized Bleeding Rate (ABR) of All Bleeding Episodes During Prophylaxis Treatment in Part A1.86 ± 2.543.38 ± 4.17
PrimaryAnnualized Bleeding Rate (ABR) of All Bleeding Episodes Within 48 Hours of Previous Prophylaxis Infusion in Part B

Annualized number (mean +/- standard deviation) of all bleeding episodes that occurred within 48 hours of previous prophylaxis infusion is reported for previously untreated/minimally treated patients (PUPs/MTPs). All bleeding episodes: sum of spontaneous bleeds and trauma bleeds exclude bleeding due to surgery.

Time frame:
Up to 48 hours post-infusion during 6 months
Reported as:
Mean · Bleed per year
Annualized Bleeding Rate (ABR) of All Bleeding Episodes Within 48 Hours of Previous Prophylaxis Infusion in Part B
Bleed per yearPart B: PUPs <6 YearsPart B: MTPs <6 Years
Annualized Bleeding Rate (ABR) of All Bleeding Episodes Within 48 Hours of Previous Prophylaxis Infusion in Part B0.00 ± 0.000.00 ± 0.00
SecondaryAnnualized Bleeding Rate (ABR) of All Bleeding Episodes Within 48 Hours of Previous Prophylaxis Infusion in Part A

Annualized number (mean +/- standard deviation) of all bleeding episodes that occurred within 48 hours of previous prophylaxis infusion is reported for previously treated patients (PTPs). All bleeding episodes: sum of spontaneous bleeds and trauma bleeds exclude bleeding due to surgery.

Time frame:
Up to 48 hours post-infusion during 6 months
Reported as:
Mean · Bleed per year
Annualized Bleeding Rate (ABR) of All Bleeding Episodes Within 48 Hours of Previous Prophylaxis Infusion in Part A
Bleed per yearPart A: PTPs <12 YearsPart A: PTPs ≥12 Years
Annualized Bleeding Rate (ABR) of All Bleeding Episodes Within 48 Hours of Previous Prophylaxis Infusion in Part A2.26 ± 3.101.36 ± 2.19
SecondaryAnnualized Bleeding Rate (ABR) of All Bleeding Episodes During Prophylaxis Treatment in Part B

Annualized number (mean +/- standard deviation) of all bleeding episodes that occurred during the prophylaxis treatment period is reported for previously untreated/minimally treated patients (PUPs/MTPs). All bleeding episodes: sum of spontaneous bleeds and trauma bleeds exclude bleeding due to surgery.

Time frame:
Up to 51 exposure days
Reported as:
Mean · Bleed per year
Annualized Bleeding Rate (ABR) of All Bleeding Episodes During Prophylaxis Treatment in Part B
Bleed per yearPart B: PUPs <6 YearsPart B: MTPs <6 Years
Annualized Bleeding Rate (ABR) of All Bleeding Episodes During Prophylaxis Treatment in Part B1.13 ± 1.602.05 ± 0
SecondaryNumber of Infusions Per Bleeding Episode

The mean value of number of infusions for the treatment of one bleed to achieve hemostasis is reported.

Time frame:
Part A: up to 6 months; Part B: up to 51 exposure days
Reported as:
Mean · Infusion
Number of Infusions Per Bleeding Episode
InfusionPart A: PTPs <12 YearsPart A: PTPs ≥12 YearsPart B: PUPs <6 YearsPart B: MTPs <6 Years
Number of Infusions Per Bleeding Episode1.78 ± 2.281.45 ± 1.2914.00 ± 0.001.00 ± 0.00
SecondaryNumber of Surgeries Per Physician's Assessment of Adequacy of Hemostasis in Minor Surgery

For participants who underwent minor surgeries during the study, investigators were ask to assess the adequacy of hemostasis during the surgeries as excellent, good, moderate or poor. Number of surgeries per assessment is reported.

Time frame:
Part A: up to 6 months; Part B: up to 51 exposure days
Reported as:
Number · surgery
Number of Surgeries Per Physician's Assessment of Adequacy of Hemostasis in Minor Surgery
surgeryPart A: PTPs <12 YearsPart A: PTPs ≥12 YearsPart B: PUPs <6 YearsPart B: MTPs <6 Years
Total minor surgeries22——
Surgeries with EXCELLENT adequacy of hemostasis22——
SecondaryFVIII In-vivo Recovery in Part B

Incremental recovery of Factor VIII (FVIII) was determined by collecting blood samples pre-infusion and 15-30 minutes after the end of the infusion. Mean recovery values at different time points are reported.

Time frame:
At baseline, Visit 6 (ED 20), unscheduled visit and final visit, up to 51 exposure days
Reported as:
Mean · IU/dL per IU/kg
FVIII In-vivo Recovery in Part B
IU/dL per IU/kgPart B: PUPs <6 YearsPart B: MTPs <6 Years
Baseline (Unscheduled visit for PUP)1.90 ± 0.001.86 ± 0.00
Visit 6 (ED 20)0.91 ± 0.001.22 ± 0.00
Final visit1.55 ± 0.00—
SecondaryFactor VIII Inhibitor Development by the Nijmegen Bethesda Assay

Number of participants who developed a positive Factor VIII (FVIII) inhibitor level (≥0.6 Bethesda unit \[BU/mL\]) during the study is reported.

Time frame:
Part A: up to 6 months; Part B: up to 51 exposure days
Reported as:
Count of participants · Participants
Factor VIII Inhibitor Development by the Nijmegen Bethesda Assay
ParticipantsPart A: PTPs <12 YearsPart A: PTPs ≥12 YearsPart B: PUPs <6 YearsPart B: MTPs <6 Years
Factor VIII Inhibitor Development by the Nijmegen Bethesda Assay0000
SecondaryNumber of Participants With Treatment-emergent Adverse Events

An adverse event (AE) was any untoward medical occurrence in a participant, associated with the use of study intervention, whether or not considered related to the study intervention. A serious adverse event (SAE) was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening; persistent or significant disability/incapacity; congenital anomaly/birth defect; another medical important serious event as judged by the investigator. AEs or SAEs were considered to be treatment emergent (TEAEs or TESAEs) if they started after the first KOVALTRY infusion and up to 3 days after the last dose.

Time frame:
Part A: up to 6 months; Part B: up to 51 exposure days
Reported as:
Count of participants · Participants
Number of Participants With Treatment-emergent Adverse Events
ParticipantsPart A: PTPs <12 YearsPart A: PTPs ≥12 YearsPart B: PUPs <6 YearsPart B: MTPs <6 Years
Any TEAE13311
Maximum intensity for any TEAE - Mild10311
Maximum intensity for any TEAE - Moderate2000
Maximum intensity for any TEAE - Severe1000
Any study drug-related TEAE1000
Any TESAE2000
TEAE with outcome death0000
Other pre-specifiedNumber of Participants Without Bleeding Episode

Number of participants who did not experience any bleed during the prophylaxis treatment period or within 48 hours of previous prophylaxis infusion is reported.

Time frame:
During prophylaxis treatment in Part A: up to 6 months; Part B: up to 51 exposure days
Reported as:
Count of participants · Participants
Number of Participants Without Bleeding Episode
ParticipantsPart A: PTPs <12 YearsPart A: PTPs ≥12 YearsPart B: PUPs <6 YearsPart B: MTPs <6 Years
During prophylaxis treatment13710
Within 48 hours16821
Other pre-specifiedNumber of Bleeds Per Assessment of Response to Treatment of Bleeds

Participants or caregivers were asked to assess the response to treatment of bleeds as excellent, good, moderate or poor. Number of bleeds per assessment is reported.

Time frame:
Part A: up to 6 months; Part B: up to 51 exposure days
Reported as:
Number · Bleeds
Number of Bleeds Per Assessment of Response to Treatment of Bleeds
BleedsPart A: PTPs <12 YearsPart A: PTPs ≥12 YearsPart B: PUPs <6 YearsPart B: MTPs <6 Years
Total bleeds511111
Bleeds without response assessment to treatment7100
Bleeds with EXCELLENT response to treatment4500
Bleeds with GOOD response to treatment25201
Bleeds with MODERATE response to treatment14310
Bleeds with POOR response to treatment1000
SecondaryFVIII In-vivo Recovery in Part A

Incremental recovery of Factor VIII (FVIII) was determined by collecting blood samples pre-infusion and 15-30 minutes after the end of the infusion. Mean recovery values at different time points are reported.

Time frame:
At baseline, Month 2 and final visit, up to 6 months
Reported as:
Mean · IU/dL per IU/kg
FVIII In-vivo Recovery in Part A
IU/dL per IU/kgPart A: PTPs <12 YearsPart A: PTPs ≥12 Years
Baseline1.82 ± 0.262.03 ± 0.46
Month 21.86 ± 0.322.12 ± 0.42
Final visit1.85 ± 0.332.06 ± 0.37
SecondaryMaximum Observed Concentration of FVIII in Plasma (Cmax) in Part A

For the assessment, participants were administered a dose of 50 IU/kg KOVALTRY. Participants must have no signs or symptoms of an acute bleeding episode. For participants below 12 years, the evaluation was only performed once at baseline. For adolescents/adult participants 12 years or older, the evaluation was performed twice at baseline and at final visit.

Time frame:
at baseline for PTPs < 12 Years and at baseline and final visit (month 6) for PTPs >= 12 Years
Reported as:
Geometric mean · IU/dL
Maximum Observed Concentration of FVIII in Plasma (Cmax) in Part A
IU/dLPart A: PTPs <12 YearsPart A: PTPs ≥12 Years
Baseline95.20 ± 15.24114.64 ± 15.77
Final Visit/ Early Termination—115.95 ± 17.47
SecondaryArea Under the Plasma Concentration of FVIII Versus Time Curve From Zero to Infinity (AUC) in Part A

For the assessment, participants were administered a dose of 50 IU/kg KOVALTRY. Participants must have no signs or symptoms of an acute bleeding episode. For participants below 12 years, the evaluation was only performed once at baseline. For adolescents/adult participants 12 years or older, the evaluation was performed twice at baseline and at final visit.

Time frame:
at baseline for PTPs < 12 Years and at baseline and final visit (month 6) for PTPs >= 12 Years
Reported as:
Geometric mean · h*IU/dL
Area Under the Plasma Concentration of FVIII Versus Time Curve From Zero to Infinity (AUC) in Part A
h*IU/dLPart A: PTPs <12 YearsPart A: PTPs ≥12 Years
Baseline1292.97 ± 22.871519.38 ± 32.38
Final Visit/ Early Termination—1559.29 ± 26.16
SecondaryHalf-life (t1/2) of FVIII in Plasma in Part A

For the assessment, participants were administered a dose of 50 IU/kg KOVALTRY. Participants must have no signs or symptoms of an acute bleeding episode. For participants below 12 years, the evaluation was only performed once at baseline. For adolescents/adult participants 12 years or older, the evaluation was performed twice at baseline and at final visit.

Time frame:
at baseline for PTPs < 12 Years and at baseline and final visit (month 6) for PTPs >= 12 Years
Reported as:
Geometric mean · Hour
Half-life (t1/2) of FVIII in Plasma in Part A
HourPart A: PTPs <12 YearsPart A: PTPs ≥12 Years
Baseline10.3655 ± 21.2211.8605 ± 19.25
Final Visit/ Early Termination—11.2630 ± 17.29

Adverse events

Collected over From the first infusion to three days after last infusion, an average of 6 months for Part A and 4 months for Part B. Adverse event reporting for deaths (all causes) considers all deaths that occurred at any time during the study before the last contact. Adverse event reporting for deaths (all causes) considers all deaths that occurred at any time during the study before the last contact.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Part A: PTPs >=12 Years0/12 (0%)0/12 (0%)3/12 (25%)
Part A: PTPs <12 Years0/30 (0%)2/30 (6.7%)8/30 (26.7%)
Part B: PUPs <6 Years0/2 (0%)0/2 (0%)1/2 (50%)
Part B: MTPs <6 Years0/1 (0%)0/1 (0%)1/1 (100%)
Most frequent serious events
Most frequent serious events
EventPart A: PTPs >=12 YearsPart A: PTPs <12 YearsPart B: PUPs <6 YearsPart B: MTPs <6 Years
HaemarthrosisMusculoskeletal and connective tissue disorders0/121/300/20/1
EpilepsyNervous system disorders0/121/300/20/1
Most frequent other events
Most frequent other events
EventPart A: PTPs >=12 YearsPart A: PTPs <12 YearsPart B: PUPs <6 YearsPart B: MTPs <6 Years
Respiratory tract infectionInfections and infestations0/120/300/21/1
COVID-19Infections and infestations0/120/300/21/1
DiarrhoeaGastrointestinal disorders0/120/301/20/1
CoughRespiratory, thoracic and mediastinal disorders0/120/301/20/1
RhinorrhoeaRespiratory, thoracic and mediastinal disorders0/120/301/20/1
Upper respiratory tract infectionInfections and infestations1/125/300/20/1
TonsillitisInfections and infestations0/124/300/20/1
Duodenal ulcerGastrointestinal disorders1/120/300/20/1
HypertensionVascular disorders1/120/300/20/1

Baseline characteristics

Age, Customized
Age, Customized(Participants)Part A: PTPs <12 YearsPart A: PTPs ≥12 YearsPart B: PUPs <6 YearsPart B: MTPs <6 YearsTotal
Infants and toddlers (28 days-23 months)00101
Children (2-11 years)3001132
Adolescents (12-17 years)05005
Adults (18-64 years)07007
Sex: Female, Male
Sex: Female, Male(Participants)Part A: PTPs <12 YearsPart A: PTPs ≥12 YearsPart B: PUPs <6 YearsPart B: MTPs <6 YearsTotal
Female00000
Male30122145
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Part A: PTPs <12 YearsPart A: PTPs ≥12 YearsPart B: PUPs <6 YearsPart B: MTPs <6 YearsTotal
American Indian or Alaska Native00000
Asian30122145
Native Hawaiian or Other Pacific Islander00000
Black or African American00000
White00000
More than one race00000
Unknown or Not Reported00000
08

Study locations

10 sites
  • Beijing Children's Hospital, Capital Medical University
    Beijing, Beijing 100045, China
  • The Children's Hospital Zhejiang University School of Med
    Hangzhou, Hangzhou Province 310056, China
  • Shijiazhuang General Hospital
    Shijiazhuang, Hebei 50000, China
  • NJ Drum Tower Hospital, the Affil Hos of NJ Univ Med School
    Nanjing, Jiangsu 210008, China
  • 1st Affiliated hospital of Soochow University
    Suzhou, Jiangsu 215000, China
  • Jiangxi Provincial People's Hospital
    Nanchang, Jiangxi 330006, China
  • Children's Hospital of Shanxi
    Taiyuan, Shanxi 30013, China
  • Chengdu Women & Children's Central Hospital
    Chengdu, Sichuan 610091, China
  • Peking Union Medical College Hospital CAMS
    Beijing, 100730, China
  • Childrens Hospital of Shanghai
    Shanghai, TBC, China
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No — Availability of this study's data will later be determined according to Bayer's commitment to the EFPIA/PhRMA "Principles for responsible clinical trial data sharing". This pertains to scope, timepoint and process of data access. As such, Bayer commits to sharing upon request from qualified researchers patient-level clinical trial data, study-level clinical trial data, and protocols from clinical trials in patients for medicines and indications approved in the US and EU as necessary for conducting legitimate research. This applies to data on new medicines and indications that have been approved by the EU and US regulatory agencies on or after January 01, 2014. Interested researchers can use www.vivli.org to request access to anonymized patient-level data and supporting documents from clinical studies to conduct research. Information on the Bayer criteria for listing studies and other relevant information is provided in the member section of the portal.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Sep 2020 to primary completion in Mar 2024, 41 months.

Results were first posted in Apr 2025, 1 year 1 month after primary completion.

Of 40 phase 4 interventional studies under Hemophilia A, half reached primary completion within 31 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 112. This study's 41 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 4, 2020
First posted
Sep 25, 2020
StartActual
Sep 22, 2020
Primary completionActual
Mar 15, 2024
CompletionActual
Mar 15, 2024
Results first posted
Apr 18, 2025
Last update
Apr 18, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 18, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04565236
Lead sponsor
Bayer
Responsible party
Sponsor
First posted
Sep 25, 2020
Start date
Sep 22, 2020
Primary completion
Mar 15, 2024
Completion
Mar 15, 2024
Results posted
Apr 18, 2025
Last update
Apr 18, 2025

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion